highperformr logo

Cerevel Therapeutics's Overview

Total employees70
HeadquartersCambridge
Founded

Cerevel Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel therapies for a broad range of neuroscience diseases. Spun out from Pfizer in 2018 with foundational investment from Bain Capital, Cerevel focuses on advancing a differentiated pipeline targeting conditions such as schizophrenia, Parkinson's disease, epilepsy, and dementia-related apathy. Their approach combines a deep understanding of brain neurocircuitry with expertise in drug development to bring potentially transformative treatments to patients. In December 2023, AbbVie announced a definitive agreement to acquire Cerevel Therapeutics, aiming to enhance its neuroscience portfolio.

Where is Cerevel Therapeutics's Headquarters?

HQ Function

The Cambridge headquarters serves as the central hub for Cerevel's research and development activities, clinical operations, corporate strategy, and general administrative functions.

Notable Features:

The facility likely includes state-of-the-art laboratory spaces, modern office layouts designed for collaboration, and is situated to leverage the dense biotech ecosystem of Kendall Square.

Work Culture:

Cerevel's work culture is reported to be dynamic and science-driven, emphasizing innovation, collaboration among multidisciplinary teams, and a strong patient-centric focus to address significant unmet medical needs in neuroscience.

HQ Significance:

Its location in Cambridge provides strategic advantages, including access to a rich talent pool, leading academic and research institutions, and a vibrant community of biotech peers and potential partners.

Values Reflected in HQ: The headquarters' location and design likely reflect Cerevel's commitment to cutting-edge science, innovation, and fostering a collaborative environment to accelerate the development of new medicines.

Location:

Cerevel Therapeutics's primary operational footprint, including R&D and corporate functions, is centered in the United States. While direct international office locations are not prominently listed, the company's clinical development programs for its therapeutic candidates may involve trial sites and collaborations across multiple countries, managed through its US base or via contract research organizations (CROs). Its global reach is expected to expand upon successful product approvals and commercialization strategies, particularly under the pending acquisition by AbbVie.

Street Address:

222 Jacobs Street, Suite 200

City:

Cambridge

State/Province:

Massachusetts

Country:

USA

Cerevel Therapeutics's Global Presence

Buying Intent Signals for Cerevel Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Cerevel Therapeutics

As of April 2025, Cerevel Therapeutics' leadership includes:

Ron Renaud - President and Chief Executive Officer
John Renger, Ph.D. - Chief Scientific Officer
Raymond Sanchez, M.D. - Chief Medical Officer
Susan Altschuller, Ph.D. - Chief Financial Officer
Kathleen T. O’Brien - Chief People Officer
Bryan Phillips - Chief Legal Officer and Corporate Secretary
Paul Frye - Chief Development Operations Officer

Investors of Cerevel Therapeutics

Cerevel Therapeutics has been backed by several prominent investors over the years, including:

Bain Capital (Founding Investor)
Pfizer (Contributed foundational assets)
Was publicly traded (NASDAQ: CERE) with various institutional and retail investors prior to acquisition agreement.
AbbVie (Acquiring company, deal pending completion)

Executive New Hires/Exits in the Last 12 Months

Hire1
Exits2

Over the past year, Cerevel Therapeutics has experienced key leadership adjustments, most notably the appointment of a new Chief Financial Officer. These changes come as the company continues to advance its clinical pipeline and prepares for its pending acquisition by AbbVie.

Departures

Abraham Ceesay, Abraham Ceesay departed from his role as Chief Operating Officer.
Scott Akamine, Scott Akamine departed from his role as Chief Financial Officer.

New Appointments:

Susan Altschuller, Ph.D., Susan Altschuller, Ph.D., was appointed as the new Chief Financial Officer, effective June 3, 2024.

Technology (Tech Stack) used by Cerevel Therapeutics

Discover the tools Cerevel Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Cerevel Therapeutics Email Formats and Examples

Cerevel Therapeutics likely utilizes standard corporate email address formats. The most common patterns for companies of its structure and industry are [first_initial][last]@[companydomain.com] or [first].[last]@[companydomain.com].

first.last@cerevel.com

Format

jane.doe@cerevel.com

Example

85%

Success rate

News and media

Cerevel Therapeutics Investor RelationsMay 9, 2024

Cerevel Therapeutics Appoints Susan Altschuller, Ph.D., as Chief Financial Officer

Cerevel Therapeutics announced the appointment of Susan Altschuller, Ph.D., as its new Chief Financial Officer, effective June 3, 2024. Dr. Altschuller succeeds Mark Bodenrader, who served as interim CFO....more

AbbVie News CenterDecember 6, 2023

AbbVie to Acquire Cerevel Therapeutics

AbbVie announced a definitive agreement to acquire Cerevel Therapeutics for $45.00 per share in cash, valuing the company at approximately $8.7 billion. This acquisition is intended to significantly strengthen AbbVie's neuroscience pipeline with Cerevel's portfolio of promising clinical and preclinical assets....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Cerevel Therapeutics, are just a search away.